Objective-To elucidate the downstream mechanisms of vascular endothelial growth factor receptor 2 (VEGFR2), a key receptor in angiogenesis, which has been associated with atherosclerotic plaque growth and instability. Methods and Results-By using a yeast-2-hybrid assay, we identified A Disintegrin And Metalloprotease 10 (ADAM10) as a novel binding partner of VEGFR2. ADAM10 is a metalloprotease with sheddase activity involved in cell migration; however, its exact function in endothelial cells (ECs), angiogenesis, and atherosclerosis is largely unknown. For the first time to our knowledge, we show ADAM10 expression in human atherosclerotic lesions, associated with plaque progression and neovascularization. We demonstrate ADAM10 expression and activity in ECs to be induced by VEGF; also, ADAM10 mediates the ectodomain shedding of VEGFR2. Furthermore, VEGF induces ADAM10-mediated cleavage of vascular endothelium (VE)-cadherin, which could increase vascular permeability and facilitate EC migration. Indeed, VEGF increases vascular permeability in an ADAM10-and ADAM17-dependent way; inhibition of ADAM10 reduces EC migration and chemotaxis.
A ngiogenesis is associated with tumor growth, metastasis, and growth and instability of atherosclerotic plaques. The latter contribute to plaque rupture and its clinical complications. 1 Expression of the major angiogenic factor, vascular endothelial growth factor (VEGF) A, increases during atherogenesis. In endothelial cells (ECs), VEGF exerts its stimulatory effect mostly via VEGF receptor (VEGFR) 2 (kinase insert domain receptor [KDR]/fetal liver kinase-1 [Flk-1]) and is a potent angiogenic mediator of EC migration, proliferation, and survival. 2 VEGF binding induces VEGFR2 dimerization, followed by (auto)phosphorylation on tyrosine residues. Activation of VEGFR2 induces signaling via phospholipase C (PLC)␥, activation of the mitogen-activated protein kinase/extracellular signal-regulated kinase (ERK) 1/2 pathway, and EC proliferation. Furthermore, activation of p38 -mitogen-activated protein kinase or phosphatidylinositol 3-kinase (PI3K) leads to EC migration, survival, and increased permeability. 2, 3 
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In addition to angiogenesis, VEGF and its receptors are associated with development of atherosclerosis, plaque angiogenesis, and plaque instability. Recently, it was suggested that VEGF may induce a more vulnerable plaque phenotype by promoting leukocyte recruitment. 4 DNA vaccination against VEGFR2 in low-density lipoprotein receptor-defia-cient mice inhibited atherosclerotic plaque growth by reducing plaque neovascularization. 5 Treatment with a neutralizing anti-VEGFR1 antibody reduced atherosclerosis in apolipoprotein E Ϫ/Ϫ mice via inhibition of leukocyte infiltration, whereas anti-VEGFR2 was ineffective. 6 The neutralizing VEGF antibody bevacizumab (Avastin) is an effective anticancer therapy that inhibits tumor angiogenesis; however, it is associated with an increase in cardiovascular adverse effects based on thrombosis and plaque instability. 7 Unraveling downstream VEGFR signaling mechanisms involved in angiogenesis and atherosclerosis will identify novel therapeutic targets and, therefore, will open perspectives for more specific and effective therapeutic interventions.
In this study, we aimed to identify novel binding partners of VEGFR2 involved in downstream VEGFR signaling by using yeast-2-hybrid screening. We identified A Disintegrin And Metalloprotease 10 (ADAM10), a metalloprotease with ␣-secretase activity, as a novel candidate interacting with VEGFR2. ADAM10 is required for cleavage of membrane proteins involved in adhesion, migration, and chemotaxis and has been implicated in cancer progression. 8 ADAM10deficient mice are embryonically lethal because of defects in cardiovascular and neural development. 9 Our data show, for the first time to our knowledge, a functional interaction between VEGFR2 and ADAM10 and a role of ADAM10 in (VEGF-induced) EC function. In addition, we provide initial evidence for the expression of ADAM10 in human atherosclerotic plaques, associated with neovascularization.
Methods

Coimmunoprecipitation and In Vitro Kinase Assay
These assays, combined with SDS-PAGE, were performed as previously described, 2 with minor modifications. Additional details are available in the supplemental data (available online at http://atvb.ahajournals.org).
Fluorogenic Peptide Cleavage Assay
ECs were cultured in a 96-well plate and serum starved overnight once 70% to 90% confluence was reached. Cells were pretreated for 30 minutes with 10-mol/L LY294002, PD98059, or SB203580. Medium was replaced by Hanks balanced salt solution containing 10-mol/L Mca-PLAQAV-Dpa-RSSSR-NH2 fluorogenic peptide substrate. ECs were stimulated with 5-or 50-ng/mL VEGF, 20-ng/mL phorbol 12myristate 13-acetate (PMA), or 5-mol/L ionomycin in the presence of 5-mol/L GI54023X, 5-mol/L GW280264X, or dimethyl sulfoxide (DMSO). Increase of fluorescence was measured at 405 nm (excitation at 320 nm) for 6 hours using a fluorescence microplate reader.
Statistical Analysis
Values are expressed as meanϮSEM of at least 3 experiments, and a 2-tailed unpaired Student t test was used to compare groups. PϽ0.05 was considered significant.
Results
Identification of ADAM10 as a Novel VEGFR2 Binding Partner
By using yeast-2-hybrid screening with the intracellular domain of human VEGFR2 as bait, we aimed to identify novel binding partners involved in downstream VEGFR2 mechanisms. Five screens were performed using a cDNA library of human pla-centa as angiogenic tissue. As depicted in supplemental Table I , of 990 clones, 93 were positive for ␤-galactosidase and were retransfected for confirmation of the interaction, yielding 20 candidates for interaction with VEGFR2. Sequence analysis of these clones revealed ADAM10 as a novel binding partner of VEGFR2, with sequence coverage of 94% and identity of 100%. As positive controls for our screening, non-catalytic region of tyrosine kinase adaptor protein 1 (NCK) adaptor protein and PI3K were found; both proteins are known to be involved in VEGFR2 signaling. 2, 10 
ADAM10 Is Expressed in Human Atherosclerotic Lesions and Associated With Angiogenesis
Because the role of ADAM10 in vascular function and disease was largely unknown, we first investigated ADAM10 expression in human vascular wall and atherosclerotic plaques using immunohistochemical staining. ADAM10 expression is low in healthy vessel wall (mammary artery, supplemental Figure IA ) and early human atherosclerotic lesions ( Figure 1A , nϭ5) but is significantly increased during plaque progression from early and advanced to ruptured atherosclerotic plaques ( Figure 1B and C, nϭ8 and 5, respectively), as determined by semiquantitative analysis (supplemental Table II ) and confirmed by quantitative PCR analysis of human atherosclerotic plaque specimens (PϽ0.01, nϭ6 to 7) ( Figure 1D ). ADAM10 was expressed in most cell types (ie, smooth muscle cells and macrophages), especially in foam cells ( Figure 1E ); most interestingly, ADAM10 was highly expressed in ECs of plaque microvessels ( Figure 1F ), as confirmed by double staining for ADAM10 and CD31 ϩ / CD34 ϩ ECs (supplemental Figure IB) . In addition, we demonstrated high expression of ADAM10 in human colon cancer cells and the microvessels within, but not surrounding, the colon tumor ( Figure 1G and H, nϭ5; and supplemental Table III ). These data further strengthen our finding of a functional association between ADAM10 and angiogenesis.
ADAM10 Interacts With VEGFR2 and Mediates VEGFR2 Ectodomain Shedding
To validate the interaction of VEGFR2 and ADAM10, as identified in our yeast-2-hybrid screening, we performed coimmunoprecipitation experiments. VEGFR2 or ADAM10 was precipitated from porcine aortic ECs overexpressing human VEGFR2 (porcine aortic endothelial cells [PAEC]-KDR) or untransfected PAECs stimulated with 0-to 50-ng/mL VEGF. Tyrosine-phosphorylated proteins were detected in precipitated immune complexes using an in vitro tyrosine kinase assay and separation of protein complexes by SDS-PAGE. In VEGFR2 precipitates of PAEC-KDR, a strongly phosphorylated protein, corresponding to the size of human VEGFR2 (approximately 250 kDa) was detected; this protein was absent from untransfected PAECs that do not express detectable levels of endogenous VEGFR2 (Figure 2A ). As expected for VEGFR2, phosphorylation of this protein significantly increased after VEGF stimulation, strongly indicating this was, indeed, VEGFR2. In ADAM10 precipitates, several phosphorylated proteins could be detected. In unstimulated PAEC-KDR, phosphorylated VEGFR2 could barely be detected, whereas after VEGF stimulation, phosphorylated VEGFR2 was clearly detectable as a coprecipitate of ADAM10, supporting the yeast-2-hybrid results of the VEGFR2 and ADAM10 interaction. Because VEGFR2 expression in primary human ECs is much lower than in PAEC-KDR, VEGFR2 coimmunoprecipitating with ADAM10 in these cells was below the detection limit (data not shown).
ADAM10 is involved in the juxtamembrane cleavage of several cell surface molecules and receptors, thereby releasing their ectodomains (shedding). 11 Because the related metalloprotease ADAM17 has been implicated in VEGFR2 shedding, we examined whether the interaction between ADAM10 and VEGFR2 provides a basis for ADAM10mediated ectodomain shedding of VEGFR2. PAEC-KDR cells were incubated for 5 hours with 2 hydroxamate-based inhibitors of ADAM10. The inhibitor GI254023X blocks ADAM10 with a Ͼ100-fold higher potency compared with ADAM17, whereas compound GW280264X blocks both ADAM10 and ADAM17. 12 Inhibition of ADAM10 by 5-mol/L GI254023X, a concentration that selectively blocks ADAM10 activity, and inhibition of both ADAM10 and ADAM17 by GW280264X significantly reduced constitutive release of the VEGFR2 ectodomain in PAEC-KDR culture medium compared with dimethyl sulfoxide-treated controls ( Figure 2B and C, PϽ0.001). Release of soluble (s)VEGFR2 slightly increased after VEGF stimulation, which was again significantly decreased after inhibition of ADAM10 only or both ADAM10 and ADAM17. Because PAEC-KDR cells overexpress the human VEGFR2 and the proportion shed by the (limited) amount of ADAM10 available in these cells will be limited, no differences in amount of full-length VEGFR2 in PAEC-KDR lysate were found ( Figure 2B , lower panel).
VEGF Induces ADAM10 Expression in ECs
In addition to a physical interaction, we examined the functional interaction between ADAM10 and the VEGFR2 pathway to determine whether ADAM10 is involved in downstream VEGFR2 functions. VEGF increased ADAM10 mRNA expression up to 34% in PAEC-KDR (data not shown) and human umbilical vein ECs (HUVECs) (PՅ0.01, supplemental Figure II ). In addition to mRNA, we analyzed VEGF-induced ADAM10 protein expression in ECs. In HUVECs, ADAM10 is expressed as an approximately 135-kDa proenzyme that is processed into an approximately 90-kDa mature and active enzyme ( Figure 3A and B ). VEGF stimulation of HUVECs for 24 hours significantly induced total ADAM10 protein expression up to 1.95-fold (PϽ0.01, Figure 3C ). Most interestingly, short-term stimulation with VEGF resulted in a 2.1-fold increase of processed and mature (ie, active) ADAM10 in HUVECs (PϽ0.01, Figure 3D ).
Similar results were found in PAEC-KDR (data not shown). These data indicate that VEGF stimulation of ECs not only induces total ADAM10 expression at both the mRNA and protein level but could also induce the processing of the latent enzyme into the activated ADAM10 protein.
ADAM10 Activity in ECs Is Induced by VEGF
To confirm ADAM10 activation by VEGF stimulation in ECs, we used a fluorogenic peptide as a substrate; this peptide emits a fluorescent signal when degraded. As expected, PMA and ionomycin induced peptide degradation in HUVECs. Stimulation with 50-ng/mL VEGF significantly induced peptide degradation in 6 hours by 1.4-fold in HUVECs (PϽ0.05, Figure 3E ). Because this peptide can also be degraded by ADAM17 and ADAM9, the inhibitors GI254023X and GW280264X were used to determine the contribution of ADAM10 to VEGF-induced peptide degradation. Inhibition of ADAM10 alone by GI254023X reduced basal peptide degradation by 10% (Pϭ0.08). Interestingly, VEGF-induced peptide degradation was not significantly stimulated anymore when ADAM10 was inhibited by GI235024X ( Figure 3E ). Combined ADAM10 and ADAM17 inhibition by GW280264X reduced basal and VEGF-induced peptide degradation (18% [PϽ0.01] and 41% [PϽ0.001], respectively). Similar results were found in PAEC-KDR (data not shown).
VEGF stimulates several signaling pathways by VEGFR2 activation. 2,3 Therefore, we used specific inhibitors to identify the signaling pathways required for VEGF-induced ADAM10 activity. In nonstimulated HUVECs, inhibition of PI3K, p38, and ERK1/2 activation slightly, but not significantly, reduced basal peptide degradation. Interestingly, a VEGF-dependent increase of peptide degradation was significantly inhibited by ERK1/2 inhibition (PϽ0.05). Similar results were found by PI3K inhibition, whereas no significant effects were seen with p38 inhibition (supplemental Figure III) . These data indicate that VEGF induces ADAM10 (and ADAM17) activity in ECs via ERK1/2 and potentially PI3K signaling.
VEGF Induces ADAM10-Mediated VE-Cadherin Cleavage, Increasing Permeability
ADAM10 can cleave several adhesion molecules (eg, N-cadherin, E-cadherin, and the endothelial-specific VEcadherin). 13 Cleavage of VE-cadherin increased endothelial permeability and T-cell transmigration, 2 important processes in angiogenesis and atherosclerosis. To investigate whether VEGF could induce this functional activity of ADAM10, we stimulated HUVECs for 24 hours with VEGF in the presence or absence of GI254023X or GW280264X. The ␥-secretase inhibitor N-[N-(3,5-difluorophenacetyl)-l-alanyl]-S-phenylglycine t-butyl ester (DAPT) (10 mol/L) was used to prevent further intracellular processing of VE-cadherin after initial cleavage by ADAM10, allowing quantification of the cleaved intracellular fragment ( Figure 4A ). Both GI254023X and GW280264X completely blocked cleavage of VE-cadherin, confirming the role of ADAM10 in cleavage of this EC adhesion molecule ( Figure  4B ). Interestingly, VEGF stimulation increased VE-cadherin cleavage by 41% (Pϭ0.02), which was prevented by ADAM10 inhibition (PϽ0.01). Results of pharmacological inhibition of ADAM10 and ADAM17 on VE-cadherin cleavage were con- firmed using an RNA interference (RNAi) approach. HUVEC transfection with specific ADAM10 small interference RNAs resulted in specific knockdown of ADAM10 protein (70% to 80%) without affecting ADAM17 expression (supplemental Figure IV) . Similarly, specific ADAM17 knockdown (50% to 60%) was found without a significant effect on ADAM10 expression. Interestingly, specific knockdown of ADAM10 significantly inhibited VE-cadherin cleavage in HUVECs (60% reduction, PϽ0.0001 for unstimulated HUVECs) ( Figure 4C and D). ADAM17 knockdown in HUVECs did not block VE-cadherin. This indicates the involvement of ADAM10, but not ADAM17, in VE-cadherin cleavage in HUVECs.
Because ADAM10-mediated VE-cadherin cleavage increased vascular permeability and leukocyte transmigration, we investigated whether VEGF could mediate its effect on vascular permeability by ADAM10. HUVECs were grown to confluence, and electric resistance was measured using an electric cell substrate impedance sensing system. Electric resistance of HUVECs without VEGF treatment remained constant throughout the experiment (data not shown). As expected, after a transient increase in resistance, VEGF induced a gradual decline in cellular resistance, corresponding to increased permeability ( Figure 4E) . A similar VEGF-induced decline in resistance was found when only ADAM10 was inhibited by GI254023X. However, combined inhibition of ADAM10 and ADAM17 by GW280264X attenuated the VEGF-induced decline in resistance ( Figure 4E ). This indicates that, although ADAM10 inhibition alone is sufficient to block VE-cadherin cleavage, VEGF-induced EC permeability is regulated by both ADAM10 and ADAM17, probably involving cleavage of other cell-cell adhesion molecules in addition to VE-cadherin.
ADAM10 Is Required for EC and Monocyte Migration and Chemotaxis
Because cleavage of adhesion molecules is essential for cell migration, we examined the requirement of ADAM10 for EC migration and chemotaxis using a Boyden chamber. Baseline EC migration (chemokinesis) was significantly reduced (by 39%) when ADAM10 was inhibited by GI254023X, whereas VEGF-induced chemotaxis was reduced by 41% (Pϭ0.005 and Pϭ0.02, respectively) ( Figure 5A ). In addition to ECs, monocytes are critical players in cardiovascular disease, not only in atherosclerosis but also by participating in neovascularization. 14 ADAM10 inhibition also significantly reduced both monocyte chemokinesis (50%, Figure 5B ) and chemotaxis (52% for VEGF and 36% for formyl-methionyl-leucylphenylalanine [fMLP]), indicating that ADAM10 is required for cell migration, most likely by facilitating cell detachment by cleavage of cell adhesion molecules.
By using an electric cell substrate impedance sensing system, we measured the migratory healing response of HUVECs after wounding by a high electric field. In control cells, resistance returned to steady-state conditions within 8 hours after wounding, indicating that the response is rather a result of EC migration than proliferation ( Figure 5C ). Inhibition of ADAM10 by GI254023X delayed this woundhealing response, which was even more pronounced when both ADAM10 and ADAM17 were inhibited by GW280264X.
Discussion
In this study, we identified ADAM10 as a novel mediator of VEGF-induced EC function and provided the first evidence of ADAM10 interaction with VEGFR2. VEGF induces both ADAM10 expression and activity. We showed ADAM10 to be required for VEGF-induced VE-cadherin cleavage, vascular permeability, and EC migration. To our knowledge, this is the first report to document ADAM10 expression in human atherosclerotic lesions associated with atherosclerotic plaque progression and neovascularization. By using a yeast-2-hybrid screening, we identified ADAM10 as a novel binding candidate for VEGFR2, which was supported by coimmunoprecipitation of VEGFR2 with ADAM10 in PAEC-KDR. This interaction could be of functional significance in endothelial biology. Recently, Swendeman et al 15 showed the highly related ADAM17 to mediate VEGFR2 shedding, which could be induced by VEGF. For ADAM10, they reported a role in shedding of neuropilin-1, the coreceptor for VEGFR2. In this study, we showed not only ADAM17, but also ADAM10, to be involved in VEGFR2 ectodomain shedding. Shedding of VEGFR2 and neuropilin-1 could provide a mechanism to modulate VEGFR2 signaling (eg, as a negative feedback loop to dampen the VEGF stimulatory signal). Such an interaction would be transient, which might also explain why we could only find a little VEGFR2 coprecipitating with ADAM10.
In addition to a physical interaction, we demonstrated a functional interaction between ADAM10 and the VEGFR2 pathway. We found VEGF to induce not only ADAM10 expression but, more important, to stimulate its proteolytic activity. The exact mechanism of activation of ADAM10 by VEGF remains to be elucidated. In this study, we found evidence of ERK1/2 involvement in the VEGF-induced peptide-degrading activity of ADAM10 (although the involvement of ADAM9 and ADAM17 cannot be excluded in this assay). VEGF is known to increase intracellular Ca 2ϩ levels by activating PLC. 16 Increased intracellular Ca 2ϩ induces ADAM10 processing (ie, activation) by furinlike proteases. 17 Whether induction of ADAM10 activity by VEGF is dependent on Ca 2ϩ influxes and activity of furin or other proteases remains to be determined.
In this study, we showed VEGF to stimulate cleavage of the endothelial-specific adhesion molecule VE-cadherin by ADAM10, but not ADAM17, using both pharmacological inhibitors and specific small interference RNAs for ADAM10 and ADAM17. Recently, VE-cadherin cleavage has been shown to increase EC permeability and T-cell transmigration. 18 VEGF is well-known to induce endothelial permeability by promoting phosphorylation, endocytosis of VEcadherin, and subsequent disruption of adherent junctions. 19 Our data clearly demonstrate a role for ADAM10, but also ADAM17, in VEGF-induced EC permeability. Although VE-cadherin cleavage was nearly completely abrogated when only ADAM10 was inhibited, VEGF-mediated HUVEC permeability was only attenuated by inhibition of both ADAM10 and ADAM17. This might be explained by ADAM10/ ADAM17-mediated cleavage of other EC junctional adhesion molecules that are involved in regulating endothelial permeability. Recently, Koenen et al 20 showed that cleavage of junctional adhesion molecule-1 in ECs was predominantly mediated by ADAM17 and, to a lesser extent, by ADAM10. Because junctional adhesion molecule-1 is also involved in regulating endothelial permeability, 21 this might explain why it is necessary to inhibit both ADAM10 and ADAM17 to effectively block a VEGF-mediated increase in permeability, even though ADAM10 inhibition alone is sufficient to block cleavage of individual adhesion molecules (ie, VE-cadherin). Increased EC permeability has also been implicated in progression and rupture of atherosclerotic lesions, in which the microvasculature has been proposed to be immature and "leaky." 22 Consequently, leukocytes can transmigrate through the endothelium more easily and enter the atherosclerotic plaque, where they can contribute to plaque progression and destabilization.
In addition to adhesion molecules, ADAM10 is known to be involved in shedding numerous chemotactic and inflam-matory molecules, such as CXC chemokine ligand (CXCL)-16, fractalkine, interleukin 6 receptor, tumor necrosis factor ␣, receptor for advanced glycation endproducts (RAGE), and CD40L, 23 all known to contribute to atherogenesis and plaque progression. Therefore, it is not surprising that we found increased ADAM10 expression in advanced human atherosclerotic plaques with many infiltrating cells and a high degree of inflammation. Furthermore, we found high ADAM10 expression associated with plaque and tumor neovascularization. ADAM10 has been implicated in the proteolytic cleavage of several proteins regulating arteriogenic and angiogenic processes (eg, members of the Notch pathway 24 and ephrin [ligands]). 25 Recently, VEGF was shown to induce shedding of the angiopoietin receptor Tie-2, which likely is mediated by ADAM10. Furthermore, VEGFinduced Notch activation in ECs was ADAM10 dependent (V.C., M.M.P.C.D., J.W., D.G.M.M. and M.J.P., unpublished data, 2010). Activation of Notch is involved in the regulation of vessel sprouting, 27 which, in addition to inhibiting EC migration, provides another mechanism by which ADAM10 inhibition could modulate neovascularization responses. These functional data of a role of ADAM10 in (VEGFinduced) EC functions, together with our finding of a direct interaction between ADAM10 and the VEGFR pathway, which by shedding of the VEGFR2 could modulate VEGFR2 signaling and downstream EC functions, strengthen the hypothesis that ADAM10 plays a crucial role in various mechanisms underlying angiogenic and atherosclerotic processes. Furthermore, these findings may also have important implications for other diseases in which neovascularization contributes to disease progression, such as cancer.
In addition to ADAM10, other ADAM proteins may be involved in the angiogenic and atherosclerotic processes. As previously mentioned, ADAM17 is related to ADAM10 and shares several substrates. Nevertheless, differences in regulation between ADAM10 and ADAM17 functions have been reported (ie, in pathways leading to activation of the proteases, in constitutive versus regulated proteolytic activity, and in substrate specificity). 13, 15, 28 Interestingly, ADAM17 expression has been associated with both atherosclerotic lesion progression and resistance to atherosclerosis in mice. 29, 30 Recently, ADAM17 was shown to be involved in endothelial tube formation in vitro and pathological neovascularization in vivo. 31 Pathological retinal neovascularization and growth of heterotopically injected tumor cells were reduced in mice that lack ADAM17 specifically in the ECs. Furthermore, ADAM15 has mediated inflammation and was associated with atherosclerosis. 32 Therefore, it will be important to further elucidate the exact mechanisms of ADAM functions in cardiovascular diseases and most challenging to determine the specificity of ADAM10 functions compared with related ADAMs. In this study, we used 2 approaches to inhibit ADAM10 and ADAM17 activities (ie, the hydroxamatebased compounds GI254023X and GW280264X, which were designed to discriminate between ADAM10 and ADAM17 12 ; and specific knockdown of either ADAM10 or ADAM17 using small interference RNA). Both approaches showed similar results. However, to identify the involvement of other distinct ADAM proteases in (VEGF-induced) EC functions, additional selective inhibitors are needed. Furthermore, it will be important Figure 5 . A, GI254023X, 5 mol/L, reduces PAEC-KDR migration and chemotaxis toward 10-ng/mL VEGF. B, GI254023X reduces monocyte migration and chemotaxis toward 10-ng/mL VEGF and 10 Ϫ8 -mol/L fMLP. *PϽ0.05 (nϭ3). C, GI254023X and GW280264X, 5 mol/L, reduces HUVEC migration response after applying a high electric field.
to determine the role of ADAM10 in neovascularization and cardiovascular diseases in vivo. Because ADAM10 Ϫ/Ϫ mice are embryonically lethal, 9 this will require the use of conditional knockout models.
In conclusion, this study shows, for the first time to our knowledge, expression of ADAM10 in atherosclerotic lesions, associated with neovascularization. This provides the first evidence of an interaction between the VEGFR2 pathway and ADAM10 and a functional role of ADAM10 in (VEGF-induced) EC functions. Therefore, these data open perspectives for novel therapeutic interventions in neovascularization and vascular diseases.
